Novo Nordisk A/S

$ 48.39 -0.12 (-0.25%)
Volume: 1,127,664 Avg Vol (1m): 1,266,637
Market Cap $: 116.48 Bil Enterprise Value $: 114.19 Bil
P/E (TTM): 20.35 P/B: 15.00
Earnings Power Value 25.6
Net Current Asset Value 0.01
Tangible Book 2.91
Projected FCF 28.49
Median P/S Value 44.6
Graham Number 12.47
Peter Lynch Value 31.98
DCF (FCF Based) 43.47
DCF (Earnings Based) 63.78
YTD (-%)

Financial Strength : 8/10

Current vs industry vs history
Cash-to-Debt 30.37
Equity-to-Asset 0.47
Debt-to-Equity 0.01
Debt-to-EBITDA 0.01
Interest Coverage 26.92
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.05
DISTRESS
GREY
SAFE
Beneish M-Score -2.53
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 115.66%
WACC 8.56%

Profitability & Growth : 9/10

Current vs industry vs history
Operating Margin % 42.25
Net Margin % 34.54
ROE % 79.65
ROA % 37.74
ROC (Joel Greenblatt) % 129.38
3-Year Total Revenue Growth Rate 1.20
3-Year Total EBITDA Growth Rate 4.60
3-Year EPS w/o NRI Growth Rate 5.60

» NVO's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:NVO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2836
Compare NAS:AMGN NAS:GILD NAS:CELG ASX:CSL NAS:BIIB LSE:SHP NAS:VRTX NAS:REGN XKRX:068270 XKRX:207940 NAS:ALXN HKSE:01177 XMCE:GRF.P NAS:BMRN XBRU:UCB NAS:NKTR OCSE:NZYM B NAS:INCY OCSE:GEN NAS:BIVV
Traded in other countries NNOR.Austria NOVO B.Denmark NOVA.Germany NVON.Mexico NOVOB.Switzerland 0QIU.UK
Address Novo Alle, Bagsvaerd, DNK, 2880
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Ratios

Current vs industry vs history
PE Ratio (TTM) 20.35
Forward PE Ratio 19.96
N/A
PE Ratio without NRI 20.35
Price-to-Owner-Earnings 18.96
PB Ratio 15.00
PS Ratio 7.00
Price-to-Free-Cash-Flow 24.33
Price-to-Operating-Cash-Flow 17.56
EV-to-EBIT 15.29
EV-to-EBITDA 14.17
EV-to-Revenue 6.75
PEG Ratio 1.75
Shiller PE Ratio 28.15
Current Ratio 1.09
Quick Ratio 0.79
Days Inventory 329.97
Days Sales Outstanding 74.37
Days Payable 139.98

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 2.59
Dividend Payout Ratio 0.49
3-Year Dividend Growth Rate (Per Share) 16.20
Forward Dividend Yield % 2.59
N/A
Yield-on-Cost (5-Year) % 6.18
3-Year Share Buyback Rate 2.30

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 16.66
Price-to-Projected-FCF 1.70
Price-to-DCF (Earnings Based) 0.76
Price-to-Median-PS-Value 1.08
Price-to-Peter-Lynch-Fair-Value 1.52
Price-to-Graham-Number 3.89
Earnings Yield (Joel Greenblatt) % 6.54
Forward Rate of Return (Yacktman) % 17.39

More Statistics

Revenue (TTM) (Mil) $ 17,630.95
EPS (TTM) $ 2.51
Beta 0.83
Volatility % 19.03
52-Week Range $ 41.23 - 52.83
Shares Outstanding (Mil) 2,386

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N